Search

Your search keyword '"Jayanthi J. Wolf"' showing total 43 results

Search Constraints

Start Over You searched for: Author "Jayanthi J. Wolf" Remove constraint Author: "Jayanthi J. Wolf"
43 results on '"Jayanthi J. Wolf"'

Search Results

1. Characterization of integration frequency and insertion sites of adenovirus DNA into mouse liver genomic DNA following intravenous injection

2. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

3. Vaccine Development in the Midst of Ebolavirus Disease Outbreaks

4. Scientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists

5. The impact of export regulations on recombinant viral vaccine development for emerging infectious diseases

6. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens

7. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges

8. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic

9. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates

10. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment

11. An Evaluation of the Impact of PD‐1 Pathway Blockade on Reproductive Safety of Therapeutic PD‐1 Inhibitors

12. Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease

13. Evaluation of a 9-valent HPV vaccine in Sprague-Dawley rats: Nonclinical studies assessing general, reproductive, and developmental toxicity

14. Reliable quantification of mRNA in archived formalin-fixed tissue with or without paraffin embedding

15. A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates

16. A multi-species assay for siRNA-mediated mRNA knockdown analysis without the need for RNA purification

17. Lack of effects on male fertility from a quadrivalent HPV vaccine in Sprague-Dawley rats

18. Application of PCR technology in vaccine product development

19. Using QPCR to assign infectious potencies to adenovirus based vaccines and vectors for gene therapy: toward a universal method for the facile quantitation of virus and vector potency

21. Contributors

22. Special Considerations for the Nonclinical Safety Assessment of Vaccines

23. Strategies for the Nonclinical Safety Assessment of Vaccines

24. Nonclinical safety assessment of vaccines and adjuvants

25. Nonclinical Safety Assessment of Vaccines and Adjuvants

26. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats

27. Quantifying the titer and quality of adenovirus stocks

29. Quantifying the Titer and Quality of Adenovirus Stocks

31. Ensuring the quality, potency and safety of vaccines during preclinical development

32. 893. Using QPCR and Automation to Assign Infectious Potencies to Adenovirus Based Vaccines and Vectors for Gene Therapy

33. Characterization of integration frequency and insertion sites of adenovirus DNA into mouse liver genomic DNA following intravenous injection.

34. Development of Pandemic Vaccines: ERVEBO Case Study.

35. Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease.

36. The impact of export regulations on recombinant viral vaccine development for emerging infectious diseases.

37. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).

38. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens.

39. Scientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists.

40. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates.

41. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.

42. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.

43. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.

Catalog

Books, media, physical & digital resources